Boehringer Ingelheim’s Animal Health marks 15 years of success in Vietnam

This milestone was celebrated with a special event attended by nearly 190 customers, highlighting the company’s commitment to customer-centricity and collaboration in delivering first-in-class innovative solutions for the livestock and companion animal segments.

Since its establishment in 2008, the animal health business in Vietnam has forged strong relationships and partnerships with its customers and business partners.

“This anniversary serves as a testament to the unwavering trust and support of our customers and business partners. Their collaboration has been instrumental in our journey towards sustainable growth and enhanced health care for animals in Vietnam,” said Dr. Armin Wiesler, Country Managing Director and Head of Animal Health, Regional Operating Unit ASEAN, Korea, Australia & New Zealand.

Driven by the purpose of bringing “Value through innovation”, Boehringer Ingelheim has launched more than 40 animal health products over the past 15 Years in Vietnam. The company’s portfolio includes vaccines, parasite-control products, therapeutics complemented by diagnostics and monitoring platforms to help protect and treat disease in pets and livestock. Many of them became best in class brands, such as Parasiticides of the Frontline® and Nexgard® family as well as Recombitec® vaccines in Pets, Ingelvac PRRS® MLV, Ingelvac CircoFLEX®, Ingelvac MycoFLEX® and the Enterisol® vaccine range in swine, Vaxxitek®, Newxxitec®, PREVEXXION® RN and Gallimune® range of Poultry vaccines.

Dr. Torsten Hardge, Director of Animal Health, Boehringer Ingelheim Vietnam, said, “Innovation and our expertise in animal health are at the core of Boehringer Ingelheim’s business activities globally and in Vietnam. We are passionate in bringing cutting-edge innovations to our customers, integrate smart digital technologies like Soundtalks – which supports early detection of respiratory disease in pigs and introduce e-commerce solutions for convenient access of our pet products. As a result, we are positively impacting the lives of animals and humans in Vietnam.”  

Apart from the relentless effort to bring innovative pharmaceutical solutions for humans and animals, Boehringer Ingelheim commits to contribute its expertise and heritage to make meaningful advances towards rabies elimination, especially in underserved communities. Through STOP Rabies program in Vietnam, in collaboration with the Department of Agriculture and Rural Development in Duc Hue District People’s Committee, 20,000 dogs and cats have been vaccinated against rabies since 2021 and are on track to eliminate dog-mediated rabies in the Long An province by 2025. In addition, 1,000 students have been educated about rabies and dog bite prevention, in efforts to raise awareness and knowledge about rabies in communities, especially among children.  

Working towards to carbon neutrality in the company’s operations by 2030, Boehringer Ingelheim Vietnam will continue to reduce its carbon footprint and operational waste of solutions, in order to mitigate the environmental impact of its business. 

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health.